UKHSA IPC for seasonal respiratory infections guideline
Covering the infection prevention and control principles required to prevent transmission of COVID-19 and other respiratory viruses for winter 2021–2022
UKHSA staff with symptoms of a respiratory infection guideline
Covering the management of healthcare staff with symptoms of a respiratory infection, including COVID-19 and positive COVID-19 test results
GOLD COPD 2022 strategy
A clear summary of GOLD’s 2022 strategy on COPD diagnosis, management, and prevention, including recommendations on COVID-19 and COPD
NICE obstructive sleep apnoea guideline
Covering the diagnosis and management of OSAHS, and the assessment of OHS and COPD–OSAHS overlap syndrome in people over 16
NICE bronchiolitis guideline
A brief summary of the NICE guideline on bronchiolitis in babies and children, including advice on when to refer, and 'red flags' for parents
NICE asthma guideline: chronic asthma management
A practical summary of NICE recommendations on managing chronic asthma in children, young people, and adults, including three management algorithms
NICE asthma guideline: diagnosis and monitoring
A concise summary on the initial assessment, diagnosis, and monitoring of asthma in adults, young people, and children. Includes assessment algorithms
COVID-19 rapid guideline on cystic fibrosis
The purpose of this Guidelines summary is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic.
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.
Resource hub
Inhaler standards and competency document
- Previous
- Next
Educational resources
DuoResp® Spiromax® (budesonide/formoterol)
This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.
Click here for prescribing information and adverse event reporting
DUOR-GB-00117
Date of preparation: March 2022
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.